So what:Bristol-Myers Squibb (NYS: BMY) and Johnson & Johnson (NYS: JNJ) just partnered up to study a two-company drug cocktail to treat chronic hepatitis C. The giants hope to find an effective hep-C treatment that doesn't rely on interferons and other injections with severe side effects -- and Idenix's IDX184 happens to target exactly that market.